INTERCEPT PHARMACEUTICALS INC 4
4 · INTERCEPT PHARMACEUTICALS INC · Filed Jan 9, 2014
Insider Transaction Report
Form 4
TALLARIGO LORENZO
Director10% Owner
Transactions
- Sale
Common Stock
[F1]2014-01-07$67.41/sh−1,839$123,967→ 1,640 total
Holdings
- 5,938,890(indirect: See Footnote)
Common Stock
[F2]
Footnotes (2)
- [F1]The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on December 18, 2013.
- [F2]Held by Genextra S.p.A. Dr. Tallarigo is the chief executive officer of Genextra S.p.A. and, in such capacity, Dr. Tallarigo exercises voting control over the shares of common stock owned by Genextra S.p.A. and investment control over such shares as authorized by the board of directors of Genextra S.p.A. Dr. Tallarigo disclaims beneficial ownership with respect to any such shares, except to the extent of his pecuniary interest therein, if any.
Signature
/s/ Bryan Yoon, attorney-in-fact|2014-01-09